Cipla said its discussions with Moderna on the Covid-19 booster vaccine are nearing finalisation and for that, they are seeking the 'partnership and support of the government to make this programme successful'.
Photo used for representational purpose. Pic/AFP
Requesting the government to provide confirmation on four critical points — exemption from price restriction, indemnification, bridging trial waiver and basic customs duty exemption, Cipla has said such an assurance will help make this significant financial commitment of more than $1 billion (over ₹7,250 crore) advance to Moderna for its booster vaccine in India, sources privy to the development said.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.
